arrow
Y

Yih-Giun Cherng

taipei medical university
H指数:24
被引数:2,105

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “LARS inhibition overcomes regorafenib resistance in hepatocellular carcinoma via ferroptosis and drug metabolism” [European Journal of Pharmaceutical Sciences 225 (2026)107614]

勘误:“LARS抑制通过铁死亡和药物代谢克服肝细胞癌中的瑞戈非尼耐药性” [欧洲药理学杂志 225 (2026)107614]

2026-10-250
OAAI
Targeting PPP1R15B and ATF4 Axis in Hepatocellular Carcinoma: A Novel Strategy for Overcoming Lenvatinib-Tolerant Persister Cells Through GPX4-Mediated Ferroptosis Induction

靶向PPP1R15B和ATF4轴在肝细胞癌中的研究:一种通过GPX4介导的铁死亡诱导克服仑伐替尼耐受持久性细胞的创新策略

2026-01-080
OAAI
The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies

台湾精准医学计划提供了一个队列用于大规模研究

Nature
IF48.5
2025-10-150
PRE
Preoperative use of selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors and adverse outcomes after liver surgery: A Nationwide propensity score-matched study

术前选择性5-羟色胺再摄取抑制剂和5-羟色胺-去甲肾上腺素再摄取抑制剂的使用与肝脏手术后不良结局的关系:一项全国性倾向性评分匹配研究

2025-10-140
PRE
Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study

与术前胰高血糖素样肽-1受体激动剂使用相关的围手术期心肺并发症和死亡率风险:一项全国性倾向性评分匹配研究

2025-09-110
PRE